相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anatomic patterns of relapse and progression following treatment with 131I-MIBG in relapsed or refractory neuroblastoma
Rotem Fishel Ben Kenan et al.
PEDIATRIC BLOOD & CANCER (2022)
Radiopharmaceutical Chemistry and Drug Development-What's Changed?
Charles A. Kunos et al.
SEMINARS IN RADIATION ONCOLOGY (2021)
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The Hopeful Eight
Romain Eychenne et al.
PHARMACEUTICS (2021)
Revisiting the Radiobiology of Targeted Alpha Therapy
Jean-Pierre Pouget et al.
FRONTIERS IN MEDICINE (2021)
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
Sture Lindegren et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2020)
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Human dosimetry of free211At andmeta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice
Naoyuki Ukon et al.
EJNMMI PHYSICS (2020)
Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
Andreas Hallqvist et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Development of Targeted Alpha Particle Therapy for Solid Tumors
Narges K. Tafreshi et al.
MOLECULES (2019)
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Jo Lynne Rokita et al.
CELL REPORTS (2019)
Anti-tumor effects and potential therapeutic response biomarkers in α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing
Yasuhiro Ohshima et al.
THERANOSTICS (2019)
Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model
Yasuhiro Ohshima et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Mehran Makvandi et al.
TARGETED ONCOLOGY (2018)
Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations
Vandana Batra et al.
PEDIATRIC BLOOD & CANCER (2017)
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles
Oscar R. Pozzi et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
Mehran Makvandi et al.
CANCER RESEARCH (2016)
Neuroblastoma
Katherine K. Matthay et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study
Gregory A. Yanik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Nothing but NET: A Review of Norepinephrine Transporter Expression and Efficacy of I-131-mIBG Therapy
Keri A. Streby et al.
PEDIATRIC BLOOD & CANCER (2015)
A systematic review of 131 I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
Jayne S. Wilson et al.
EUROPEAN JOURNAL OF CANCER (2014)
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
JulieAnn Rader et al.
CLINICAL CANCER RESEARCH (2013)
Tumor Dosimetry Using [124I]m-iodobenzylguanidine MicroPET/CT for [131I]m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model
Youngho Seo et al.
MOLECULAR IMAGING AND BIOLOGY (2012)
Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program
Vandana Batra et al.
PEDIATRIC BLOOD & CANCER (2012)
Safety and Efficacy of Tandem 131I-Metaiodobenzylguanidine Infusions in Relapsed/Refractory Neuroblastoma
Kelsey Johnson et al.
PEDIATRIC BLOOD & CANCER (2011)
Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors
Rob J. Mairs et al.
SEMINARS IN NUCLEAR MEDICINE (2011)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Medical Progress: Recent Advances in Neuroblastoma.
John M. Maris
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2-A Phase I Study
Hakan Andersson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
Steven G. DuBois et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
Clinical experience with alpha-particle-emitting At-211: Treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6
Michael R. Zalutsky et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Astatine Radiopharmaceuticals: Prospects and Problems
Ganesan Vaidyanathan et al.
CURRENT RADIOPHARMACEUTICALS (2008)
The pediatric preclinical testing program: Description of models and early testing results
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2007)
In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neurobtastoma
Paxton V. Dickson et al.
JOURNAL OF PEDIATRIC SURGERY (2007)
A kit method for the high level synthesis of [211At]MABG
Ganesan Vaidyanathan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma
TI Kang et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
Local delivery of 131I-MIBG to treat peritoneal neuroblastoma
S Kinuya et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
分享论文
